Sugi Predict

Sugi Predict / Compounds / SCHEMBL408373

SCHEMBL408373

SCHEMBL408373

CC(C)(C)COP(=O)(N1CCN(C(=O)c2ccc(-c3nnn[nH]3)cc2)CC1)C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RBP4 P02753 1/20 0.36
▸ PLA2G2A P14555 1/20 0.36
▸ FASN P49327 1/20 0.35
▸ STK25 O00506 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ ABL1 P00519 2/20 0.34
▸ BCR P11274 2/20 0.34
▸ LSS P48449 2/20 0.34
▸ ALDH1A1 P00352 4/20 0.33
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ HTT P42858 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ TSHR P16473 2/20 0.32
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15030737 0.80 GAA (0.40) PLA2G2ALSSALDH1A1MEN1KMT2A
SCHEMBL8947386 0.73 HPGD (0.57) HDAC4ALDH1A1MEN1KMT2AHPGD
SCHEMBL19542472 0.69 FASN (0.63) FASN
SCHEMBL15154808 0.67 GAA (0.56) ALDH1A1KMT2ASMN1; SMN2HPGDLMNA
SCHEMBL408376 0.66 — —
SCHEMBL26054508 0.65 PGR (0.38) ALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL21485419 0.64 CHRNB2 (0.43) HPGDSLC6A7MAPK1
SCHEMBL16598891 0.64 GPR183 (0.62) —
SCHEMBL16598889 0.64 GPR183 (0.62) —
SCHEMBL408997 0.64 USP2 (0.34) RBP4ALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11732259-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2023-08-22 — — US disclosed
US-11732259-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2023-08-22 — — US disclosed
US-11225662-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2022-01-18 — — US disclosed
US-20210139897-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS SAREPTA THERAPEUTICS, INC. 2021-05-13 — — US disclosed
US-20210139896-A1 Peptide Oligonucleotide Conjugates JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2021-05-13 — — US disclosed
US-20200277598-A1 Peptide Oligonucleotide Conjugates JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2020-09-03 — — US disclosed
US-10760078-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups SAREPTA THERAPEUTICS, INC. (US) 2020-09-01 — — US disclosed
US-10398721-B2 Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA SAREPTA THERAPEUTICS, INC. (US) 2019-09-03 — — US disclosed
US-20190218551-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2019-07-18 — — US disclosed
US-20180092938-A1 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2018-04-05 — — US disclosed
US-9326992-B2 Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA SAREPTA THERAPEUTICS, INC. (US) 2016-05-03 — — US disclosed
US-20160102307-A1 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2016-04-14 — — US disclosed
US-9161948-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2015-10-20 — — US disclosed
US-9066967-B2 Oligonucleotide analogues targeting human LMNA SAREPTA THERAPEUTICS, INC. (US) 2015-06-30 — — US disclosed
US-20150073140-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS SAREPTA THERAPEUTICS, INC. (US) 2015-03-12 — — US disclosed
US-8779128-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups SAREPTA THERAPEUTICS, INC. (US) 2014-07-15 — — US disclosed
US-20140024821-A1 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA SAREPTA THERAPEUTICS, INC. (US) 2014-01-23 — — US disclosed
US-20140024698-A1 METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA SAREPTA THERAPEUTICS, INC. (US) 2014-01-23 — — US disclosed
US-20120289457-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES AVI BIOPHARMA, INC. (US) 2012-11-15 — — US disclosed
US-20120065169-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2012-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218551-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB RBP4 1499/4885PLA2G2A 3785/4885FASN 3581/4885
US-20120065169-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB RBP4 1499/4885PLA2G2A 3785/4885FASN 3581/4885
US-20200277598-A1 Peptide Oligonucleotide Conjugates SNRPE, SMN1; SMN2, UPF1 RBP4 1291/4885PLA2G2A 3383/4885FASN 3306/4885
US-10398721-B2 Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA LMNA, LMNB2, LMNB1 RBP4 1633/4885PLA2G2A 539/4885FASN 559/4885
US-20160102307-A1 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA LMNB2, LMNA, LMNB1 RBP4 2145/4885PLA2G2A 869/4885FASN 570/4885
US-10760078-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups NSUN2, UPF1, RTCB RBP4 1499/4885PLA2G2A 3785/4885FASN 3581/4885
US-20210139896-A1 Peptide Oligonucleotide Conjugates SNRPE, SMN1; SMN2, UPF1 RBP4 1291/4885PLA2G2A 3383/4885FASN 3306/4885
US-20150073140-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB RBP4 1499/4885PLA2G2A 3785/4885FASN 3581/4885
US-20140024698-A1 METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA LMNA, LMNB2, LMNB1 RBP4 1633/4885PLA2G2A 539/4885FASN 559/4885
US-20210139897-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB RBP4 1499/4885PLA2G2A 3785/4885FASN 3581/4885
US-20120289457-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES SNRPE, SMN1; SMN2, UPF1 RBP4 1291/4885PLA2G2A 3383/4885FASN 3306/4885
US-11225662-B2 Peptide oligonucleotide conjugates SNRPE, SMN1; SMN2, UPF1 RBP4 1291/4885PLA2G2A 3383/4885FASN 3306/4885
US-11732259-B2 Peptide oligonucleotide conjugates SNRPE, SMN1; SMN2, UPF1 RBP4 1291/4885PLA2G2A 3383/4885FASN 3306/4885
US-20180092938-A1 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA LMNB2, LMNA, LMNB1 RBP4 2145/4885PLA2G2A 869/4885FASN 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.